Aflibercept Is Proving to be a Diverse and Effectual Product


Aflibercept Is Proving to be a Diverse and Effectual Product

afliberceptClinical development of an exciting new recombinant fusion protein, Aflibercept, is underway. As an inhibitor of VEGF, or the vascular endothelial growth factor receptor, aflibercept is currently in a phase III trial for second line metastatic colorectal cancer. This trial for Aflibercept is being conducted by Sanofi-Aventis and Regeneron Pharmaceuticals. Additional trials currently in progress include a phase II trial of aflibercept for a first-line treatment of metastatic colorectal cancer, as well as a phase III trial for first-line metastatic, androgen-independent prostate cancer. Encouraging research is emerging, with findings that show aflibercept inhibiting new vessel growth and tumor vascularization in tumor models.

Aflibercept is not a stranger to the pharmaceutical scene. The FDA approved the aflibercept injection, or Eylea, for the treatment of wet age-related macular degeneration on November 21, 2011. As wet AMD is the leading cause of blindness in Americans who are 60 and older, aflibercept has shown to be an essential treatment for sight impaired older adults. By acting as an endothelial growth factor-A  inhibitor, the aflibercept injection curtails the growth of new blood vessels under the retina, thus improving the outlook for patients with macular degeneration.

Referred to by Sanofi and Regeneron as ZALTRAP™ or VEGF Trap, aflibercept has shown thus far to be efficacious for patients suffering from metastatic colorectal cancer. On June 25, 2011 Sanofi and Regeneron presented successful findings to the ESMO World Congress on Gastrointestinal Cancer. Research determined that aflibercept has ability to not only bind to VEGF-A, but also binds to VEGF-B and the placental growth factor, or PIGF, with a higher affinity than native recpetors. With a broad range of disease fighting possibilities, aflibercept is emerging as a fusion protein researchers will be seeking to study.

LGM Pharma supplies the API Aflibercept CAS# 862111-32-8 for research and development purposes, and provides client support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service